OPERATING IN WP1 – HOW DO GENETIC AND EPIGENETIC FEATURES CONTROL ENHANCER ACTIVITY?
OPERATING IN WP2 – HOW DO ENHANCERS FUNCTION WITHIN COMPLEX REGULATORY LANDSCAPES?
OPERATING IN WP3 – HOW DOES ENHANCER DEREGULATION IMPACT HUMAN DISEASES?
Salvatore Spicuglia is a group leader since 2011 at the TAGC, a multidisciplinary institute affiliated to the INSERM and Aix-Marseille University.
He is an expert in mammalian transcriptional regulation. His lab focuses on regulatory mechanisms at lymphoid-specific genes, as well as general aspect of epigenomic changes between normal and cancer cells. His lab recently implemented high-throughput reporter assays to quantitatively assess enhancer activity in mammals and used the method to address important questions regarding enhancer biology. Recent works in his lab has shed lights on a subset of gene promoters, termed Epromoters, which works as bona fide enhancers and regulates distal gene expression.
He is involved in several national (ANR, INCA, etc) and international projects (H2020, Ecos-Nord). As coordinator of the ITN Enhpathy, he is looking forward to the discovery of novel genetic and epigenetic mechanisms involved in the dysregulation of enhancers in diverse pathologies.
Alvaro Rada-IglesiasVice coordinator
Alvaro Rada Iglesias received his M.Sc. in Biology by the University of Leon in 2001, being recognized as the best academic curriculum of that year. Then, he obtained his PhD in 2007 at Uppsala University (Sweden), where he worked in the laboratory of Prof. Claes Wadelius. After a short post-doctoral work in the Linnaeaus Centre for Bioinformatics (Uppsala University, Sweden) under the supervision of Prof. Jan Komorowski, he obtained an EMBO long-term fellowship to continue his postdoctoral career in the laboratory of Prof. Joanna Wysocka at Stanford University (USA), where he stayed between 2009-2013. In 2013, he was recruited by the University of Cologne as a Junior Research Group Leader at the Centre for Molecular Medicine Cologne, where he successfully started his independent research group. This was recognized with an EMBO Young Investigator award (EMBO YIP) in 2017. In July 2018 he was recruited as a Principal Investigator by the University of Cantabria to direct his research group at the Institute of Biomedicine and Biotechnology of Cantabria (IBBTEC). Recently, he received an ERC CoG to study the function and mechanisms of action of enhancers during early mammalian development.